USE OF LONG-ACTING HUMAN RECOMBINANT SOLUBLE TUMOUR NECROSIS FACTOR Α RECEPTOR IN THE PREPARATION OF DRUGS FOR PREVENTING AND TREATING CHRONIC LIVER DISEASES AND SEVERE LIVER DAMAGE

摘要

Disclosed in the present invention is the use of a recombinant soluble tumour necrosis factor α receptor (HusTNFR) gene as a new drug. The invention uses the long-acting human recombinant soluble tumour necrosis factor α receptor of type I or type II to intervene with rats with chronic liver diseases and severe liver damage through a five animal model, the results show that the long-term human recombinant soluble tumour necrosis factor α receptor having a half-life of 12-140 hours has a good effect for preventing the appearance of chronic liver disease and severe liver damage and treating early chronic liver disease and severe liver damage, and the efficacy thereof is significantly improved compared to non-long-term HusTNFR.